Chemical genomics: massively parallel technologies for rapid lead identification and target validation

Chemical genomics is a new research paradigm with importantapplications in drug discovery. It links genomic targets withsmall-molecule chemistries thereby allowing for efficient targetvalidation and lead compound identification. ACADIA'schemical-genomics platform consists of a large and diverse small-moleculelibrary (800,000), a reference drug library (2,000), druggablegenomic targets (>300) and a cell-based functional assaytechnology (R-SATTM; Receptor Selection and AmplificationTechnology) that allows for ultra-high throughput screening(>500,000 data points/week) as well as high throughputpharmacology and profiling over a wide range of targets. Twoexamples are presented that illustrate the success of ourchemical-genomics approach: (i) The validation of inverse agonismat serotonin 5-HT2A receptors as an antipsychotic mechanismand the subsequent discovery of potent and selectively acting 5-HT2A inverse agonists, currently in preclinical development,and (ii) the discovery of the first ectopically binding subtype-selective muscarinic m1 agonist.

[1]  M. Brann,et al.  High throughput assays of cloned adrenergic, muscarinic, neurokinin, and neurotrophin receptors in living mammalian cells. , 1995, Pharmacology & toxicology.

[2]  M A Geyer,et al.  5-hydroxytryptamine2A receptor inverse agonists as antipsychotics. , 2001, The Journal of pharmacology and experimental therapeutics.

[3]  Lenz,et al.  Chemical ligands, genomics and drug discovery. , 2000, Drug discovery today.

[4]  M. P. Dillon,et al.  Muscarinic receptor ligands and their therapeutic potential. , 1999, Current opinion in chemical biology.

[5]  J. Drews.  Drug discovery: a historical perspective. , 2000, Science.

[6]  J. V. Moran,et al.  Initial sequencing and analysis of the human genome. , 2001, Nature.

[7]  S. Foord,et al.  Transgenic gene knock-outs: functional genomics and therapeutic target selection. , 2000, Pharmacogenomics.

[8]  Jürgen Drews,et al.  Innovation Deficit in the Pharmaceutical Industry , 1996 .

[9]  C. Debouck,et al.  The impact of genomics on drug discovery. , 2000, Annual review of pharmacology and toxicology.

[10]  D. Mccormick.  Sequence the Human Genome , 1986, Bio/Technology.

[11]  J A Landro,et al.  HTS in the new millennium: the role of pharmacology and flexibility. , 2000, Journal of pharmacological and toxicological methods.

[12]  D. Szymkowski.  Too many targets, not enough target validation. , 2001, Drug discovery today.

[13]  D. Middlemiss,et al.  Functional comparison of muscarinic partial agonists at muscarinic receptor subtypes hM1, hM2, hM3, hM4 and hM5 using microphysiometry , 1999, British journal of pharmacology.

[14]  Glenn E Croston,et al.  Functional cell-based uHTS in chemical genomic drug discovery. , 2002, Trends in biotechnology.

[15]  U. Hacksell,et al.  Discovery of an ectopic activation site on the M(1) muscarinic receptor. , 2002, Molecular pharmacology.

[16]  M. Murcko,et al.  Chemogenomic approaches to drug discovery. , 2001, Current opinion in chemical biology.

[17]  T. Willson,et al.  Chemical genomics: Functional analysis of orphan nuclear receptors in the regulation of bile acid metabolism , 2001, Medicinal research reviews.

[18]  D J Triggle,et al.  Pharmacological receptors: a century of discovery--and more. , 2000, Pharmaceutica acta Helvetiae.

[19]  M. Mann,et al.  Proteomics to study genes and genomes , 2000, Nature.